CompanyGraphAt a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $5.63M, lower than 95% of all stocks globally
- PositionGross margin is 100%, higher than 95% of its Biotechnology peers (median 67.1%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
909.00BKRW645.73M · vs all stocks (USD)
Revenue (TTM)
7.92BKRW5.63M · vs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
52-Week Change
-44.62%vs all stocks
Market Capitalization
909.00BKRW645.73M · vs all stocks (USD)
Enterprise Value
892.57BKRW634.06M · vs all stocks (USD)
Price to Book (MRQ)
17.45xvs Biotechnology peers
Enterprise to Revenue
112.70xvs Biotechnology peers
Enterprise to EBITDA
-25.90xvs Biotechnology peers
Gross Margin
100.00%vs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-1260.34%vs Biotechnology peers
Return on Assets (TTM)
-165.21%vs Biotechnology peers
Return on Equity (TTM)
-176.32%vs Biotechnology peers
Revenue (TTM)
7.92BKRW5.63M · vs all stocks (USD)
Quarterly Revenue Growth
-55.85%vs Biotechnology peers
Gross Profit (TTM)
7.92BKRW5.63M · vs all stocks (USD)
EBITDA (TTM)
0.00KRWvs all stocks (USD)
Net Income (TTM)
-103.81BKRW-73.74M · vs all stocks (USD)
Operating Cash Flow (TTM)
-10.85BKRW-7.71M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-103.81BKRW-73.74M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
7.92BKRWFY2025 · Dec 31, 2025Gross Profit
7.92BKRWFY2025 · Dec 31, 2025Operating Income
-14.60BKRW-10.37M · vs all stocks (USD)
Pre-tax Income
-102.79BKRWFY2025 · Dec 31, 2025Income Tax Expense
1.02BKRWFY2025 · Dec 31, 2025Net Income
-103.81BKRWFY2025 · Dec 31, 2025EBIT
-99.82BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
-34.46BKRWFY2025 · Dec 31, 2025Research & Development
15.07BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
1.21BKRWFY2025 · Dec 31, 2025Other Operating Expenses
110.45MKRWFY2025 · Dec 31, 2025Non-operating Interest Income
523.75MKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
2.97BKRWFY2025 · Dec 31, 2025Net Income from Continuing Operations
-102.79BKRWFY2025 · Dec 31, 2025Operating Cash Flow
-75.67BKRWFY2025 · Dec 31, 2025Free Cash Flow
-75.72BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
17.62BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-102.79BKRWFY2025 · Dec 31, 2025Stock-based Compensation
2.99BKRWFY2025 · Dec 31, 2025Other Non-cash Items
23.76BKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-829.63MKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
1.20BKRWFY2025 · Dec 31, 2025Capital Expenditures
-49.43MKRWFY2025 · Dec 31, 2025Net Intangibles (CF)
-71.95MKRWFY2025 · Dec 31, 2025Purchase of Investments
-28.83BKRWFY2025 · Dec 31, 2025Other Investing Activity
-10.00KRWFY2025 · Dec 31, 2025Net Investing Cash Flow
-28.88BKRWFY2025 · Dec 31, 2025Other Financing Charges
-2.68BKRWFY2025 · Dec 31, 2025Net Financing Cash Flow
46.02BKRWFY2025 · Dec 31, 2025Shares Outstanding
27.87MSharesUpdated Aug 8, 2026% Held by Insiders
20.92%vs all stocks
% Held by Institutions
14.19%vs all stocks
Total Cash (MRQ)
0.00KRWvs all stocks (USD)
Total Debt (MRQ)
1.16BKRW822.73K · vs all stocks (USD)
Current Ratio (MRQ)
7.66xvs Biotechnology peers
Book Value per Share (MRQ)
1.86KKRWUpdated Aug 8, 2026Total Assets
62.83BKRW44.64M · vs all stocks (USD)
Total Current Assets
54.88BKRWFY2025 · Dec 31, 2025Total Liabilities
3.96BKRWFY2025 · Dec 31, 2025Total Non-current Assets
7.95BKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
955.57MKRWFY2025 · Dec 31, 2025Total Current Liabilities
3.00BKRWFY2025 · Dec 31, 2025Cash Equivalents
17.62BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
17.62BKRWFY2025 · Dec 31, 2025Other Short-term Investments
35.92BKRWFY2025 · Dec 31, 2025Short-term Debt
444.95MKRWFY2025 · Dec 31, 2025Other Current Liabilities
-130.00KRWFY2025 · Dec 31, 2025Long-term Debt
749.49MKRWFY2025 · Dec 31, 2025Other Non-current Liabilities
430.00KRWFY2025 · Dec 31, 2025Common Stock (Book)
6.97BKRWFY2025 · Dec 31, 2025Retained Earnings
-208.59BKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
58.88BKRW41.83M · vs all stocks (USD)
52-Week Low
19.99KKRWUpdated Aug 8, 202652-Week High
122.63KKRWUpdated Aug 8, 202652-Week Change
-44.62%vs all stocks
50-Day MA
38.74KKRWUpdated Aug 8, 2026200-Day MA
69.69KKRWUpdated Aug 8, 2026Avg 10-Day Volume
341.03KSharesUpdated Aug 8, 2026Avg 30-Day Volume
324.05KSharesUpdated Aug 8, 2026Diluted EPS (TTM)
-7.09KKRWUpdated Aug 8, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 100%, higher than 95% of its Biotechnology peers (median 67.1%)Significant
Gross margin: 1.00Industry median: 0.67Industry P95: 1.00Peers compared: 261
Return on equity is -176.3%, lower than 95% of its Biotechnology peers (median -21.7%)Significant
Return on equity: -1.76Industry median: -0.22Industry P5: -1.66Peers compared: 261
Return on assets is -165.2%, lower than 95% of its Biotechnology peers (median -20.1%)Significant
Return on assets: -1.65Industry median: -0.20Industry P5: -0.85Peers compared: 261
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 1.00Profit Margin: 0.00
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $5.63M, lower than 95% of all stocks globallySignificant
Revenue (USD): 5,626,121.406Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Shenzhen Neptunus Bioengineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hefei Lifeon Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Tactile Systems Technology Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Lionco Pharmaceutical Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
MiMedx Group, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jianmin Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhongzhu Healthcare Holding Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Ironwood Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sinotherapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Gkht Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule